95837-11-9

Upstream product

• 272-62-8 furo[3,2-b]pyridine 
• 28310-22-7 [(3-hydroxypyridin-2-yl)methyl]trimethylazanium iodide 
• 95837-09-5 2,3-dihydrofuro<3,2-b>pyridine 
• 95837-10-8 5-nitro-2,3-dihydrofuro<3,2-b>pyridine 

Downstream Products

• 73101-90-3 5-ethyl-8-oxo-2,3,5,8-tetrahydrofuro<3,2-b><1,8>naphthyridine-7-carboxylic acid 
• 1031849-77-0 7-phenyl-1,2-dihydrofuro[2,3-e]imidazo[1,2-a]pyridine 
• 1031849-78-1 N,N-dimethyl-1-(7-phenyl-1,2-dihydrofuro[2,3-e]imidazo[1,2-a]pyridin-8-yl)methanamine 
• 1031849-79-2 (7-phenyl-1,2-dihydrofuro[2,3-e]imidazo[1,2-a]pyridin-8-yl)acetonitrile 
• 1031849-02-1 N-[2-(7-phenyl-1,2-dihydrofuro[2,3-e]imidazo[1,2-a]pyridin-8-yl)ethyl]acetamide 

Relevant academic research and scientific papers

Cyclic gyrase and topoisomerase IV inhibitor

The invention belongs to the technical field of medicament, and particularly relates to a compound shown in formula (I) (please see the formula (I) in the description), and acceptable salt, ester or stereoisomer of the compound in pharmacy. R1, R2, a ring

TRICYCLIC COMPOUND AND MEDICAL USE THEREOF

The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s), R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom, a halogen atom, a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or mercapto optionally having a substituent, Xa to Xe are each a carbon atom or a nitrogen atom, m is 0 to 2, and ring A to ring C are each a ring optionally having substituent(s), or a salt thereof, which is useful as an agent for the prophylaxis or treatment of a disease relating to an action of melatonin, and the like.

PYRIDINE COMPOUNDS AND METHODS OF THEIR USE

Novel pyridine compounds, pharmaceutical compositions containing the pyridine compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the pyridine compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.

Synthesis of antimicrobial agents. VI. Studies on the synthesis of furo[3,2-b][1,8]naphthyridine derivatives

As a part of our search for new antibacterial agents, 5-ethyl-8-oxo-5,8-dihydrofuro[3,2-b][1,8]naphthyridine-7-carboxylic acid and its 2,3-dihydrofuro derivative, the 4-aza analogue of droxacin, were synthesized and their antibacterial activities were tested. Both compounds exhibited high antibacterial activities and a broad antibacterial spectrum. In an attempt to find a suitable method for industrial-scale synthesis of these compounds, several methods for the furan ring cyclization of 6,7-disubstituted 1,8-naphthyridine-3-carboxylate derivatives were compared.